<DOC>
	<DOCNO>NCT01145846</DOCNO>
	<brief_summary>The purpose non-inferiority study compare effectiveness two induction chemotherapy regimen ( cytarabine plus idarubicin [ AI ] versus cytarabine plus high-dose daunorubicin [ AD ] ) AML . The effectiveness evaluate term complete remission ( CR ) rate .</brief_summary>
	<brief_title>Idarubicin Versus High Dose Daunorubicin Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>1 . INDUCTION CHEMOTHERAPY - For patient randomize receive Idarubicin ( Arm I , AI regimen ) give Cytarabine 200 mg/m2/day continuous iv infusion 24 hour daily 7 day ( D 1-7 ) along Idarubicin 12 mg/m2/day iv daily 3 day ( D 1-3 ) . - For patient randomize receive Daunorubicin ( Arm II , AD regimen ) give Cytarabine 200 mg/m2/day continuous iv infusion 24 hour daily 7 day ( D 1-7 ) along Daunorubicin 90 mg/m2/day iv daily 3 day ( D 1-3 ) . 2 . INTERIM BONE MARROW EXAMINATION - Bone marrow aspiration biopsy do 14 21 day start induction chemotherapy . - If bone marrow hypoplastic contain 5 % blast cell , chemotherapy defer marrow examination repeat time neutrophil 1,000/mcL platelet 100,000/mcL peripheral blood evaluation complete remission . - If 5 % blast cell persist interim later repeat bone marrow examination , course re-induction chemotherapy give . 3 . RE-INDUCTION CHEMOTHERAPY -Reinduction chemotherapy - Arm I ( AI regimen ) : Cytarabine 200 mg/m2/day continuous iv infusion 24 hour daily 5 day ( D 1-5 ) plus idarubicin 8 mg/m2/day iv daily 2 day ( D 1-2 ) - Arm II ( AD regimen ) : Cytarabine 200 mg/m2/day continuous iv infusion 24 hour daily 5 day ( D 1-5 ) plus Daunorubicin 45 mg/m2/day iv daily 2 day ( D 1-2 ) .Reinduction chemotherapy delay significant infection co-morbid medical condition . - Patients complete remission second course induction chemotherapy remove study 4 . POSTREMISSION CHEMOTHERAPY .The postremission therapy give patient arm . .For patient good- intermediate-risk cytogenetic feature unknown cytogenetics ( see appendix II ) , 4 course high-dose cytarabine give post-remission therapy . Cytarabine 3 g/m2 administer 3-hour iv infusion every 12 hour day 1 , 3 , 5 ( total six dos per course ) . .For patient high-risk cytogenetic feature ( see appendix II ) , 4 course intermediate-dose Cytarabine plus Etoposide give post-remission therapy . Cytarabine 1 g/m2 give 1-hour iv infusion day 1 6 ( total six dos per course ) Etoposide 150 mg/m2/day administer 5-hour iv infusion day 1 3 ( total three dos per course ) . .Sequential course postremission therapy give sooner every 28 day 1 week adequate marrow recovery . .Postremission chemotherapy delay significant infection co-morbid medical condition . .One two dos Cytarabine omit accord attend physician 's decision following : .Marrow recovery require 28 day . - A confluent maculopapular eruption drug-induced desquamation - Photophobia conjunctivitis unrelieved within 24 hour ophthalmic steroid drop - More 4 episode watery diarrhea per day - A fourfold increase previously normal serum aminotransferase alkaline phosphatase level total bilirubin level exceed 3.0 mg/dL .Treatment high-dose cytarabine discontinue patient severe cerebellar ataxia , confusion , central nervous system sign thought unrelated antiemetic medication . 5 . EVALUATION DURING TREATMENT .During induction consolidation chemotherapy : CBC differential ( daily ) , chemical battery electrolyte ( twice week ) , coagulation battery ( week ) , chest x-ray ( week ) . .Bone marrow examination repeat day 15 induction chemotherapy ( evaluation hypocellular marrow ) time ANC ≥ 1,000/μl platelet ≥ 100,000/μl peripheral blood ( evaluation complete remission ) . Chromosomal analysis repeat time evaluation complete remission . 6 . POST-TREATMENT FOLLOW-UP .After completion postremission treatment ( i.e . follow consolidation chemotherapy HCT ) : CBC differential ( monthly first 12 month , every 2-3 month next 4 year ) , study MRD monitoring ( indicate ) 7 . TREATMENT EVALUATION *FFICACY EVALUATION - Complete remission ( CR ) : Bone marrow blast &lt; 5 % ; absence blast Auer rod ; absence extramedullary disease ; absolute neutrophil count &gt; 1,000/mcL ; platelet count &gt; 100,000/mcL ; independence red cell transfusion ( Döhner H et al , 2010 ) . - All criterion need fulfil ; marrow evaluation base count 200 nucleated cell aspirate spicule ; ambiguous , consider repeat exam 5 7 day ; flow cytometric evaluation may help distinguish persistent leukemia regenerate normal marrow ; marrow biopsy perform case dry tap , spicule obtain ; minimum duration response require . - CR incomplete recovery ( CRi ) : All CR criterion except residual neutropenia ( &lt; 1,000/mcL ) thrombocytopenia ( &lt; 100,000/mcL ) . - Cause treatment failure - Resistant disease ( RD ) : Failure achieve CR CRi ; include patient survive ≥ 7 day follow completion initial treatment , evidence persistent leukemia blood and/or bone marrow examination . - Death aplasia : Deaths occur ≥ 7 day follow completion initial treatment cytopenic ; aplastic hypoplastic bone marrow obtain within 7 day death , without evidence persistent leukemia . - Death indeterminate cause : Deaths occur completion therapy , &lt; 7 day follow completion ; death occur ≥ 7 day follow completion initial therapy blast blood , bone marrow examination available . - Relapse : Bone marrow blast ≥ 5 % ; reappearance blast blood ; development extramedullary disease . - In case low blast percentage ( 5-10 % ) , repeat marrow perform confirm relapse . Appearance new dysplastic change closely monitor emerge relapse . In patient recently treat , dysplasia transient increase blast may reflect chemotherapy effect recovery hematopoiesis . Cytogenetics test distinguish true relapse therapy-related MDS/AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Patients previouslyuntreated acute myeloid leukemia ( 20 % blast bone marrow and/or blood ; M6 subtype may less 20 % blasts. ) . Therapyrelated leukemia leukemia myelodysplastic syndrome include . 15 year old old , 65 year young Adequate performance status ( Karnofsky score 50 ) Adequate hepatic renal function ( AST , ALT , bilirubin creatinine &lt; 2.5 x upper normal limit ) . Elevation AST ALT due hepatic infiltration leukemic cell permit . Adequate cardiac function ( left ventricular ejection fraction 45 % heart scan echocardiogram ) Signed date informed consent must obtain Patients acute promyelocytic leukemia bcrabl gene rearrangement Patients CNS leukemia Patients primary granulocytic sarcoma without bone marrow involvement Prior chemotherapy leukemia anthracycline treatment malignancy . Hydroxyurea reduction leukemic cell burden induction chemotherapy permit . Presence significant active infection Presence uncontrolled bleed Significant cardiovascular disease include myocardial infarction within previous 6 month Any coexist major illness organ failure Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible Nursing woman , pregnant woman , woman childbearing potential want adequate contraception Patients diagnosis prior malignancy unless diseasefree least 5 year follow therapy curative intent ( except curatively treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>